5 results
Primary:The primary objective is to assess the efficacy of LY2951742 300 mg every 30 days compared with placebo in reducing the frequency of weekly cluster headache attacks in patients with episodic cluster headache. The primary outcome measure will…
To compare the safety, effectiveness and performance of TM ABSORB bioabsorbable everolimus eluting vascular scaffold against XIENCE PRIME TM everolimus eluting coronary stent system in treating people with ischemic heart disease caused by de novo…
To examine whether compromised cochlear microphonic (CM) response during cochlear implant surgery results in poorer acoustic hearing preservation compared to preserved CM.
The primary objective of this study is to evaluate the safety of open-label galcanezumab within the context of expected medical practice in eligible patients with episodic or chronic cluster headache. The secondary endpoints are to characterize the…
Primary objective:The primary objective is to assess the efficacy of LY2951742 300 mg every 30 days compared with placebo in reducing the frequency of weekly cluster headache attacks in patients with chronic cluster headache. The primary outcome…